Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBF Conditioning in Haplo-PBSCT for Elderly AML Patients in CR1
NCT07563920Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Open-label, single-arm trial of thiotepa, busulfan and fludarabine in acute myeloid leukemia (AML), sponsored by Shanghai General Hospital. Primary endpoint: Relapse-Free Survival at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
thiotepabusulfanfludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07563920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563920.